To develop a radiopharmaceutical for the palliation of painful bone metastases based on the concept of bifunctional radiopharmaceuticals, we designed a bisphosphonate derivative attached to a stable 186Re-monoaminemonoamidedithiol (MAMA) chelate (186Re-MAMA-BP) to improve the instability of 186Re-HEDP. The precursor (Tr-MAMA-BP) of 186Re-MAMA-BP was synthesized by coupling the carboxyl group of the Tr-MAMA derivative with the amino group of the bisphosphonate derivative. This 186Re-labeled compound was prepared by a ligand exchange reaction using 186Re-glucoheptonate with a radiochemical yield of 32.0 ± 4.1%. In the incubation study in buffered solution (pH 7.0), 186Re-MAMA-BP was more stable than 186Re-HEDP. This suggests that 186Re-MAMA-BP is a potential radiopharmaceutical for the palliation of painful bone metastases. Copyright © 2004 John Wiley & Sons, Ltd.
为了根据双功能放射性药物的概念开发一种用于缓解骨转移疼痛的放射性药物,我们设计了一种附着于稳定的 186Re-monoaminemonoamidedithiol (MAMA) 螯合物(186Re-MAMA-BP)上的双
磷酸盐衍
生物,以改善 186Re-
HEDP 的不稳定性。186Re-MAMA-BP 的前体(Tr-MAMA-BP)是通过将 Tr-MAMA 衍
生物的羧基与
双膦酸盐衍
生物的
氨基偶联而合成的。这种 186Re 标记的化合物是通过使用 186Re- Glucoheptonate 进行
配体交换反应制备的,放射
化学收率为 32.0 ± 4.1%。在缓冲溶液(pH 值为 7.0)中的孵育研究中,186Re-MAMA-BP 比 186Re-
HEDP 更加稳定。这表明,186Re-MAMA-BP 是一种有潜力用于缓解骨转移疼痛的放射性药物。Copyright © 2004 John Wiley & Sons, Ltd. All Rights Reserved.